Congresses
Discover the pioneering technologies and innovations that power our vision for the future of eye care. Dive into abstracts of the upcoming ophthalmologic congresses, highlighting the groundbreaking advancements and solutions that shape the landscape of ophthalmology, all integral to RetInSight’s commitment to empowering eye care professionals to preserve their patients’ vision throughout their lifetime.
DOG Deutsche Ophthalmologische Gesellschaft | 28.-30. September 2023 | Berlin
Abstracts & Talks
Klicken Sie auf die Titel, um zu den einzelnen Abstracts zu gelangen
Donnerstag, 28. September, 10:15 – 10:24 Uhr, Raum: Auditorium von Graefe
Leingang, Oliver: Do07-01 | Entwicklung und Validierung von OCT-basierten Algorithmen zur präzisen Quantifizierung von geographischer Atrophie im Behandlungsverlauf
Donnerstag, 28. September, 10:24 – 10:33 Uhr, Raum: Auditorium von Graefe
Reiter, Gregor: Do07-02 | AI-basierte Flüssigkeitsüberwachung bei neovaskulärer AMD in der realen Welt – Ergebnisse aus dem Fight Retinal Blindness! Register
Donnerstag, 28. September, 10:33 – 10:42 Uhr, Raum: Auditorium von Graefe
Kellner, Ulrich: Do07-03 | Verlaufskontrolle mit automatisierten Messungen von retinalen Flüssigkeitsvolumina und Volumenänderungen in der OCT bei Patienten mit neovaskulärer altersabhängiger Makuladegeneration
Donnerstag, 28. September, 10:42 – 10:51 Uhr, Raum: Auditorium von Graefe
Frank, Sophie: Do07-04 | Ergebnisse durch ultra-hochauflösende optische Kohärenztomographie bei der Quantifizierung retinaler Schichten mithilfe von künstlicher Intelligenz
Donnerstag, 28. September, 11:09 – 11:18 Uhr, Raum: Auditorium von Graefe
Kostolna, Klaudia: Do07-07 | Struktur-Funktion-Analyse bei intermediärer AMD: Einfluss des Volumens von retikulären Pseudodrusen und der Deep-learning-basierten Photorezeptor-Integrität auf die Netzhautfunktion
Freitag, 29. September, 10:42 – 10:51 Uhr, Raum: Auditorium von Graefe
Schmidt-Erfurth, Ursula: Fr08-04 | Komplementinhibitoren-Therapie bei geographischer Atrophie (GA): Funktionelle und morphologische Wirksamkeit und klinisch relevante Biomarker
Samstag, 30. September, 10:42 – 10:51 Uhr, Raum: Auditorium von Graefe
Mai, Julia: Sa08-04 | Focal Events bei intermediärer AMD als erstes Zeichen der Konversion in eine äußere Netzhautatrophie in der prospektiven PINNACLE Studie
Publikationen
Klicken Sie auf die Titel, um zu den einzelnen Publikationen zu gelangen
Riedl, Schmidt-Erfurth: Whitepaper, 2023
OCT-based applications of artificial intelligence in the management of neovascular and atrophic age-related macular degeneration
Riedl et al: Ophthalmology Retina, 2022
The Effect of Pegcetacoplan Treatment on Photoreceptor Maintenance in Geographic Atrophy Monitored by Artificial Intelligence-Based OCT Analysis
Schmidt-Erfurth et al: Ophthalmology, 2020
Application of Automated Quantification of Fluid Volumes to Anti-VEGF Therapy of Neovascular Age-Related Macular Degeneration
Schmidt-Erfurth et al: Progress in Retinal and Eye Research, 2022
AI-based monitoring of retinal fluid in disease activity and under therapy
Vogl et al: Ophthalmology Retina, 2023
Predicting Topographic Disease Progression and Treatment Response of Pegcetacoplan in Geographic Atrophy Quantified by Deep Learning
Mai et al: Ophthalmology, 2022
Comparison of Fundus Autofluorescence Versus Optical Coherence Tomography-based Evaluation of the Therapeutic Response to Pegcetacoplan in Geographic Atrophy.
Riedl et al: Ophthalmology Retina, 2022
The Effect of Pegcetacoplan Treatment on Photoreceptor Maintenance in Geographic Atrophy Monitored by Artificial Intelligence-Based OCT Analysis.
Vogl et al: Ophthalmology Retina, 2022
Predicting Topographic Disease Progression and Treatment Response of Pegcetacoplan in Geographic Atrophy Quantified by Deep Learning.
EURETINA European Society of Retina Specialists | 05.-08. October 2023 | Amsterdam
Abstracts & Talks
Click on the titles to view the content
Thursday, 05. October 15:13 – 15:19 CEST
Room: Emerald Room I Part of session: Free Paper Session 3: AMD I
Schmidt-Erfurth: Pegcetacoplan therapy in geographic atrophy (GA): Therapeutic effects on retinal pigment epithelium (RPE) and photoreceptor (PR) integrity and function in the phase III clinical trials
Friday, 06. October 8:32 – 8:40 CEST
Room: Grand Auditorium I Part of session: Euretina Session 4: Research Session
Schmidt-Erfurth: Artificial Intelligence-Based Analysis of Pegcetacoplan Treatment in Geographic Atrophy
Friday, 06. October 9:01 – 9:07 CEST
Room: E102 I Part of session: Free Paper Session 4: Imaging I
Mai: Importance of automated OCT analysis for the longitudinal monitoring of geographic atrophy in clinical trials and the real-world.
Friday, 06. October 11:01 – 11:07 CEST
Room: E102 | Part of session: Free Paper Session 5: Diabetes & Vascular Diseases I
Gerendas: Protocol T: DME retreatment based on CST and BCVA stability – Can we do better considering intraretinal fluid volumes as disease stability criterion?
Friday, 06. October 14:51 – 14:56 CEST
Room: Speakers Corner I Part of session: Speakers’ Corner 7: AMD II
Frank: High Resolution assessment of Retinal Pigment Epithelium and Photoreceptor integrity/disease in the progression of early to late non-exudative age-related macular degeneration.
Friday, 06. October 14:56 – 15:01 CEST
Room: Speakers Corner I Part of session: Speakers’ Corner 7: AMD II
Mares: AI-based retinal fluid monitoring correlated with automated photoreceptor thickness quantification in neovascular AMD in the Fight Retinal Blindness! registry.
Saturday, 07. October 13:31 – 13:36 CEST
Room: Speakers Corner I Part of session: Speakers’ Corner 11: Imaging
Kostolna: Quantification of disease activity in neovascular age-related macular degeneration throughout the most commonly used optical coherence tomography devices.
Recorded Talks
- Chakravarty: Introducing an AI-path to identify risk of progression towards neovascular conversion of intermediate AMD
- Leingang: Automated AI-based staging and classification of large real-world OCT image data sets in age-related macular degeneration
- Reiter: Identifying patients most benefitting from pegcetacoplan by AI-guided assessment of retinal pigment epithelium (RPE) and photoreceptor (PR) integrity in geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
- Reiter: Lessons learnt from AI-based fluid monitoring and prediction of treatment outcomes in neovascular age-related macular degeneration in the Fight Retinal Blindness! Registry
- Riedl: Focal Events in intermediate AMD as first sign of conversion towards outer retinal atrophy in the prospective PINNACLE trial
- Weigert: Influence of fluid volume on the progression of fibrosis and atrophy in neovascular AMD
Papers & Publications
Click on the titles to view the content
Riedl, Schmidt-Erfurth: Whitepaper, 2023
OCT-based applications of artificial intelligence in the management of neovascular and atrophic age-related macular degeneration
Riedl et al: Ophthalmology Retina, 2022
The Effect of Pegcetacoplan Treatment on Photoreceptor Maintenance in Geographic Atrophy Monitored by Artificial Intelligence-Based OCT Analysis
Schmidt-Erfurth et al: Ophthalmology, 2020
Application of Automated Quantification of Fluid Volumes to Anti-VEGF Therapy of Neovascular Age-Related Macular Degeneration
Schmidt-Erfurth et al: Progress in Retinal and Eye Research, 2022
AI-based monitoring of retinal fluid in disease activity and under therapy
Vogl et al: Ophthalmology Retina, 2023
Predicting Topographic Disease Progression and Treatment Response of Pegcetacoplan in Geographic Atrophy Quantified by Deep Learning
Mai et al: Ophthalmology, 2022
Comparison of Fundus Autofluorescence Versus Optical Coherence Tomography-based Evaluation of the Therapeutic Response to Pegcetacoplan in Geographic Atrophy.
Riedl et al: Ophthalmology Retina, 2022
The Effect of Pegcetacoplan Treatment on Photoreceptor Maintenance in Geographic Atrophy Monitored by Artificial Intelligence-Based OCT Analysis.
Vogl et al: Ophthalmology Retina, 2022
Predicting Topographic Disease Progression and Treatment Response of Pegcetacoplan in Geographic Atrophy Quantified by Deep Learning.